• Explore /
  • Poster
  • / Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.

Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.

Abstract Poster

Authors

null

Sina Vatandoust

Flinders Medical Centre, Flinders University, Adelaide, Australia

Sina Vatandoust , Tim F Bright , M Nazim Abbas , Amitesh Chandra Roy , David I. Watson , Susan S H Gan , Alex Scott-Hoy , Jeff A Bull , Christos Stelios Karapetis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

ACTRN12614001063606

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4061)

DOI

10.1200/JCO.2019.37.15_suppl.4061

Abstract #

4061

Poster Bd #

166

Abstract Disclosures

Similar Posters

First Author: Sina Vatandoust

First Author: Yelena Y. Janjigian

First Author: Josep Tabernero

First Author: Rui-hua Xu